Current Therapies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Literature Review
DOI:
10.29303/jbt.v24i3.7395Published:
2024-08-24Downloads
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease. The European Academy of Neurology recommends treatment using corticosteroids, immunoglobulin, plasma exchange, & other treatments as treatment options for chronic inflammatory demyelinating polyradiculoneuropathy. However, several studies in recent years have shown that there is potential in the treatment of chronic inflammatory demyelinating Polyradiculoneuropathy. The aim of this literature review is to provide the latest therapy for chronic inflammatory demyelinating polyradiculoneuropathy based on guidelines as well as other information therapy alternatives. The method used in this literature review uses searches in several databases. The results of several studies show the development of chronic inflammatory demyelinating polyradiculoneuropathy therapy both pharmacologically & non-pharmacologically. The development of therapy for chronic inflammatory demyelinating polyradiculoneuropathy, namely hematopoietic stem cells & spinal cord stimulation, shows potential as a therapeutic option for patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Keywords:
CIDP, hematopoietic stem cells, spinal cord stimulation, therapy.References
Bijaksono, Y. H. (2021). Chronic Inflammatory Demyelinating Polyradiculopathy. IX(1), 1257–1264. https://e-journal.upr.ac.id/index.php/JK/article/view/2865
Bril, V., Hadden, R. D. M., Brannagan, T. H., 3rd, Bar, M., Chroni, E., Rejdak, K., Rivero, A., Andersen, H., Latov, N., Levine, T., Pasnoor, M., Sacconi, S., Souayah, N., Anderson-Smits, C., Duff, K., Greco, E., Hasan, S., Li, Z., Yel, L., & Ay, H. (2023). Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial. Journal of the peripheral nervous system : JPNS, 28(3), 436–449. https://doi.org/10.1111/jns.12573
Brun, S., de Sèze, J. and Muller, S. (2022) ‘CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention’, Immuno, 2(1), pp. 118–131. doi: 10.3390/immuno2010009.
Brun, S., de Sèze, J., & Muller, S. (2022). CIDP: Current treatments and identification of targets for future specific therapeutic intervention. Immuno, 2(1), 118–131. https://doi.org/10.3390/immuno2010009
Burman, J., Tolf, A., Hägglund, H. and Askmark, H. (2018). Autologous haematopoietic stem cell transplantation for neurological diseases. Journal of Neurology, Neurosurgery & Psychiatry, [online] 89(2), pp.147–155. doi:https://doi.org/10.1136/jnnp-2017-316271.
Cohen, J.C. and Lewis, R.A. (2020) ‘Rituximab for chronic inflammatory demyelinating polyneuropathy—a potential therapeutic option’, Muscle & Nerve, 61(5), pp. 549–551. doi:10.1002/mus.26871.
Fehmi, J., Bellanti, R., Misbah, S. A., Bhattacharjee, A., & Rinaldi, S. (2023). Treatment of CIDP. Practical neurology, 23(1), 46–53. https://doi.org/10.1136/pn-2021-002991
Feyen, L., Schaub, C., Zimmermann, J., & Nitsch, L. (2023). Parameters Associated with the Required Drug Dose of Intravenous Immunoglobulin in Stable Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology international, 15(1), 405–414. https://doi.org/10.3390/neurolint15010027
Garcia K, Wray JK, Kumar S. Spinal Cord Stimulation. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553154/
Giacobbe, A., Patel, M., Heller, S., & Chuquilin, M. (2020). Treatment-resistant CIDP in an IgG Tubulin Autoantibody Positive Patient: case report and review of the literature. RRNMF Neuromuscular Journal, 1(5), 20-24. https://doi.org/10.17161/rrnmf.v1i5.14547
Godelaine, J., Chitale, Y., De Moor, B., Mathieu, C., Ancheva, L., Van Damme, P., Claeys, K. G., Bossuyt, X., Carpentier, S., & Poesen, K. (2023). Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology(R) neuroimmunology & neuroinflammation, 10(6), e200162. https://doi.org/10.1212/NXI.0000000000200162
Hu, J., Sun, C., Lu, J., Zhao, C., & Lin, J. (2022). Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. In Journal of Neurology (Vol. 269, Issue 3). https://doi.org/10.1007/s00415-021-10646-y
Jiao, L., Xiang, Y., Li, S., Zhang, F., Ruan, X., & Guo, S. (2020). Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. Journal of neuroimmunology, 345, 577280. https://doi.org/10.1016/j.jneuroim.2020.577280
Koike, H. and Katsuno, M. (2020) ‘Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy’, Neurology and Therapy, 9(2), pp. 213–227. doi: 10.1007/s40120-020-00190-8.
Lehmann, H. C., Burke, D., & Kuwabara, S. (2019). Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. Journal of neurology, neurosurgery, and psychiatry, 90(9), 981–987. https://doi.org/10.1136/jnnp-2019-320314
Masson-Roy, J., Breiner, A., Warman-Chardon, J., Pringle, C.E., Allan, D., Bredeson, C., Huebsch, L., Kekre, N., Michael Lee Kennah, Martin, L., McDiarmid, S., Sultan Altouri, Atkins, H. and Bourque, P.R. (2021). Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Canadian journal of neurological sciences, 48(6), pp.1–7. doi:https://doi.org/10.1017/cjn.2021.30.
Mostofi A, Tavakkoli M, Bedran H, Nirmalananthan N, Pereira EAC. Spinal cord stimulation in the treatment of neuropathic pain in chronic inflammatory demyelinating polyneuropathy. J Clin Neurosci. 2019 Sep;67:255-257. doi: 10.1016/j.jocn.2019.06.006. Epub 2019 Jun 17. PMID: 31221583.
Muller, S. (2022). CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. Immuno, 2(1), 118–131. https://doi.org/10.3390/immuno2010009
Nasseri, M. and Majjhoo, A. (2020) ‘Spinal cord stimulation can provide significant relief to patients with neuropathic pain caused by CIDP (1195)’, Neurology, 94(15_supplement). doi:10.1212/wnl.94.15_supplement.1195.
Ponnala, M., Mullen, B., Nawab, K., Ullah, S., Khan, S., Ali, F., Ponnala, M., Mullen, B., Nawab, K., Ullah, S., Khan, S. and Ali, F. (2023). Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Overview, Treatment, and a Case Study. Cureus, [online] 15(10). doi:https://doi.org/10.7759/cureus.47475.
Rocha, R., Correia, F., Santos, A., & Martins, J. (2020). Adjuvant rituximab improves sensory ataxia in CIDP-related Sjögren syndrome. BMJ case reports, 13(8), e234681. https://doi.org/10.1136/bcr-2020-234681
Task Force—Second revision’, European Journal of Neurology, 28(11), pp. 3556–3583. doi: 10.1111/ene.14959.
Van den Bergh, P.Y.K., Doorn, P.A., Hadden, R.D.M., Avau, B., Vankrunkelsven, P., Allen, J.A., Attarian, S., Blomkwist‐Markens, P.H., Cornblath, D.R., Eftimov, F., Goedee, H.S., Harbo, T., Kuwabara, S., Lewis, R.A., Lunn, M.P., Nobile‐Orazio, E., Querol, L., Rajabally, Y.A., Sommer, C. and Topaloglu, H.A. (2021). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Journal of the Peripheral Nervous System, 26(3), pp.242–268. doi: https://doi.org/10.1111/jns.12455.
Verhamme, C. (2024). Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives. Therapeutics and Clinical Risk Management, Volume 20, 111–126. https://doi.org/10.2147/tcrm.s360249
License
Copyright (c) 2024 Teguh Budi Wicaksono, Gede Rama Hardy Nugraha, Rizka Ayu Maulida, Rima Cahyati Kusumadewi, Rukmanggana Satya Pratiwi, Annisa Risqi Amaliya, Ghina Shadrina Rienti Sepestian, Ilsa Hunaifi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
